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Polyomavirus BK has emerged as an important complication after kidney transplantation. Although, BK nephropathy
develops in only 1% to 5%of renal transplant recipients, its prognosis when present is very poor. Themost accepted risk
factor is the level of immunosuppressive treatment, but the serostatus of donor and recipient and the absence of human
leukocyte antigen C7 in donor and/or recipient influence the BK virus (BKV) reactivation. The gold standard in
diagnosing BKV nephropathy (BKVN) continues to be biopsy with use of immunohistochemistry for large T antigens.
Urinary decoy cells and blood BKV DNA polymerase chain reaction are used in the screening, but their positive
predictive values are poor. However, their use as predictors of the evolution of BKVN is more valuable. The reduction
of immunosuppressive therapy currently represents the first-line treatment for BKVN. Cidofovir and leflunomide can
be used when BKVN continues to progress. In the event of graft loss, retransplantation is possible with a low risk of
recurrence when the infection is no longer active.
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S ince the 1990s, renal transplantation has become the treat-mentof choice formostpatientswith end-stage renal disease
because of improvements in the quality of immunosuppression
and a lower risk of mortality. Yet, some infectious diseases have
appeared more often, leading to complications and making the
choice of therapy more difficult. Human polyoma BK virus ne-
phropathy (BKVN) is one of thesemajor clinical complications.
It affects approximately1%to5%ofkidney transplant recipients
and may lead to irreversible graft failure in 45% of affected pa-
tients (1). The first case of polyoma virus infection in a kidney
transplant patient was reported in 1971 (2). The virus was
named BK virus owing to the initials of the first patient diag-
nosed with this infection.
During the era of cyclosporine-based immunosuppres-
sion, BKVN was of no real clinical significance. The use of
new drugs such as tacrolimus and mycophenolate mofetil
(MMF) has been proven to contribute to a reduction in the
incidence of acute rejection episodes, but at the same time,
many centers have noted a concomitant rise in the incidence
of opportunistic infections caused by the BK virus (3–5).
Virology
Polyomavirus BK (BKV) has been classified in the Poly-
omaviridae family, which includes JC virus (JCV), simian vi-
rus 40 (SV40), and monkey polyomavirus. BKV and JCV are
human pathogens with different infection outcomes: BKV
causes nephritis and JCV is responsible for progressive mul-
tifocal leukoencephalopathy. Although both SV40 and JCV
have been implicated in some cases of BKVN, most cases
seem to be caused by BK virus. It has been suggested that
SV40 and the monkey polyomavirus can also infect humans
and may be related to the development of some human can-
cers (6). Geetha et al. (7) have also reported a case of bladder
carcinoma in a patient with BKVN in whom BKV was found
in the bladder and the metastatic implant. These four viruses
are very similar in structure, with DNA sequence homology.
The polyomaviruses are a family of small, nonenveloped
DNA viruses with icosahedral capsids of 40 to 44 nm in di-
ameter. The viral genomes within the capsids are circular
double-stranded DNA of 5300 base pairs, coated by host cell
histones that encode the early regulatory and late structural
proteins. The BK virus genome comprises the noncoding
control region, the early-coding region coding for the small
and large T antigens, and the late-coding region coding for
the viral capsid proteins (VP1, VP2, and VP3) and agnopro-
tein (8). For the life-cycle of the virus to be completed, the
virions must attach to the host cell plasma membrane
through the binding of viral capsid proteins (likely in the
VP-1 region) (9). After cell entry through caveola-mediated
endocytosis, the BKV migrate through the cytoplasm/endo-
plasmatic reticulum/microtubules and the nuclear pores into
the host cell nucleus. There, the uncoated mini-chromosome
is transcribed. Transcription of the early genes results in the
production of the T antigens that cause quiescent cells to
re-enter the cell cycle and thus begin replication of cellular
DNA. In permissive host cells, the T antigens, acting as regu-
latory proteins, conduct the remaining events, resulting in a
productive infection. The completion of the process consists
of viral DNA replication and transcription of late genes for
the production of structural proteins (VP1, VP2, and VP3)
that will constitute the capsid. Viral capsomeres assemble
around the daughter minichromosomes in the nucleus, to
form stable viral particles. Ultimately, host cells are lysed and
mature daughter virions are released.
Primary infection with BKV typically occurs in early
childhoodwithanadult seroprevalence rateof 80%(10,11).The
natural routeof transmissionofBKVin thegeneralpopulation is
incompletely understood, but multiple routes of infection are
likely involved. Oral transmission through contaminated food
or water has been suggested as a potential route of infection.
Other potential routes include semen, blood products, organ
transplantation (particularly renal allograft), and through the
placenta (12). Thus, in infants with respiratory infections, BKV
DNA has been amplified from 0% to 40% in urine samples and
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1% in nasopharyngeal aspirates. The most frequent symptom
associated with BKV primoinfection is an upper respiratory in-
fection. Sporadic reports of acute cystitis, with orwithout hema-
turia, have also been reported. After primary infection has re-
solved, the virus enters a latencyphase.This virus tends topersist
indefinitely in different organs, including the kidney, ureters,
brain, and lymphoid cells. Disease caused by the reactivation of
latent polyomavirus is typically not seen in the immunocompe-
tent host.However, slight changes in the immune status (during
pregnancy, in patients suffering from diabetes mellitus, human
immunodeficiency virus or cancer, and in recipients of renal or
other allograft) can lead to transient, asymptomatic, and self-
limiting viral activation, especially in the urothelium (12, 13).
BK Nephropathy
Reactivation of BKV can cause three different lesions in
renal transplant recipients: hemorrhagic cystitis; urethral ste-
nosis; and interstitial nephritis (14). Ahuja et al. (15) reported
that reactivationmay start as early as 4months posttransplan-
tation and run a course until graft failure, with a median
diagnosis time of 9.5 months. Sachdeva et al. (16) reported
that BKVNhas been diagnosed as early as 6 days and as late as
6 years postgrafting. Serum creatinine levels vary from nor-
mal (early BKVN stage A) to markedly increased (late stages
withmarked injury, BKVN stages B andC). Themost striking
feature of BK infection in kidney transplant recipients is the
lack of fever, malaise, myalgias, leukopenia, anemia, throm-
bocytopenia, or other symptoms or signs typical of viral in-
fection. Thus, the clinician must consider this potential BKV
infection in the face of renal function alteration. Reactivation
of BK virus in renal transplant is very common during the
first year posttransplantation with a prevalence of 45% to
50%, but it leads only occasionally to BKVN.
Bressollette-Bodin et al. (17) demonstrated, in a pro-
spective longitudinal study of BKV infection in 104 renal
transplant recipients, the detection of BKVDNA (BKViruria)
in the urine of a significant proportion of renal transplant
recipients, with or without renal dysfunction. Detection of
BKV DNA in plasma (BKViremia) has also been observed in
renal transplant recipients with BKVN. The overall preva-
lence of BKViruria andBKViremiawas 57%and 29%, respec-
tively. BKV replication occurs early after transplantation,
mostly within the first 3months, and can persist until the end
of the first year posttransplantation in a few patients. The
highest prevalenceofBKViruria andBKViremiawasobservedat
2 and 3 months and at 3 and 6 months posttransplantation,
respectively. The risk of detecting BKViremia increased when
viral load in theurinewasgreater than104 copies/mL.BKViruria
occurred within the first 3 months posttransplantation in more
than 80% of these patients. The highest percentages of patients
with BKViruria were observed at 2, 3, and 6 months posttrans-
plantation, and the highest viral load in the urine at 3 and 6
months.BKViremiawasdetectedwithin the first 3monthspost-
transplantation in80%ofpatients, and in the first sample in36%
of cases. Thehighest percentages of BKViremiawere observed at
3, 6, and 9months posttransplantation. BKViremia disappeared
before or at the same time as BKViruria.
The clinical course of individual patients varied, and
the reduction of viral load did not always translate into
improved graft function, probably owing to irreversible
chronic allograft lesions and, also perhaps, to the con-
founding effect of alloimmune injury. Buehrig et al. (18)
and Drachenberg et al. (19) concluded that patients with
early diagnosis had a better graft outcome with lower in-
terstitial and tubular injuries.
Risk Factors
Conflicting information has been reported on risk fac-
tors for BKVN in renal transplant recipients. Risk factorsmay
be donor or recipient related.
Among the risk factors that promote BKVN, immuno-
suppression is the most significant. The BKVN problem was
practically unknown in the 1980s and early 1990s during the
era of cyclosporine-based immunosuppression. The intro-
duction of third generation immunosuppression into general
clinical management has led to the current high prevalence of
BKVN. Specific agents, tacrolimus and MMF, are generally
believed to be associated with a higher incidence of BKVN.
High-dose tacrolimus or MMF immunosuppression in-
creases the odds ratio of developing BKVN by 13 times (20,
21). However, the single prospective trial that compared the
incidence of BKViremia and BKViruria in patients randomly
assigned to receive tacrolimus or cyclosporine demonstrated
no significant difference between the two drugs as well as no
significant association between MMF and BKVN (22, 23).
Likewise, Hirsch et al. (24) reported the first case of BKVN in
a patient treated with sirolimus and cyclosporine. Therefore,
it is more plausible that patients whose immunosuppression
is maintained at a higher level, rather than with a specific
agent, have higher incidences of BKVN. Treatment of acute
rejection with lymphocyte-depleting agents or steroid pulses
is also a risk factor for BKVN (25).
BKV infection in the transplant recipient couldbederived
from either the transplant donor or the transplant recipient. In
pediatric kidney transplant recipients, BKV infections were as-
sociated with a pretransplant BKV seronegative recipient, sug-
gesting that the recipient is not the primary source of BKV (26).
Hirsch et al. (27) reported that in adults, 85% of their recipients
with BKVN were seropositive pretransplantation, suggesting
that the high-risk group is not the seropositive donor and sero-
negative recipient transplant combination. On the other hand,
Bohl et al. (28) demonstrated the importance of the donor kid-
ney as the source of early BKV infection in the transplant recip-
ient and suggested that the human leukocyte antigen (HLA) C7
allele may be an important determinant of the ability to control
BKV infection in both the recipient and the donor. Indeed, re-
cipient pairs receiving a kidney from the same donor were con-
cordant for BKV infection, and had matched the noncoding
control region and VP1 genes that tended to vary among recip-
ients of kidneys from different donors.
Other recipient-related risk factors seem to be older
age, male gender (5), Caucasian race, diabetes mellitus, acute
rejection (29), and total HLA mismatches (27).
Donor-related risk factors seem to be the presence of
active BKV or cytomegalovirus infection, deceased donor
versus living donor transplant (30), and cold ischemia time.
Diagnosis
Histological evaluation of biopsy specimens is neces-
sary to confirm the presence of BKV reactivation in renal
transplant recipients.
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Cytology
The use of urine cytology for diagnosis of BKV infec-
tion has been documented since the 1970s. In urine, the in-
fected cells, known as decoy cells, show rounded nuclei that
are generally larger than the average transitional and tubular
cells (Fig. 1). The nuclei contain viral inclusions appearing as
dense granular basophilic cytoplasm with no surrounding
halo. Hirsch et al. (31) reported that the positive predictive
value of a “positive” decoy cell analysis to predict BKVN was
25% to 30%; however, the negative predictive value was
greater than 99%, that is, “negative” decoy analysis means no
viral nephropathy. Any further quantification of decoy cells
does not provide additional clinically relevant information.
Thus, the presence of decoy cells in a renal allograft recipient
does not necessarily mean BKVN, but simply reactivation of
the virus. Asymptomatic, urothelium shedding of viral inclu-
sion bearing decoy cells, which are a morphological marker
for viral activation, can be seen in up to 23% of healthy renal
allograft recipients.
Serology
In the early 1980s, the measurement of viral hemagglu-
tination antibodies was used to detect BKV infection. In re-
cent years, an even more sensitive method is being used for
the measurement of BKV viral load in the plasma and urine,
using the polymerase chain reaction (PCR) assay.
Urine PCR analysis has a higher sensitivity but lower
specificity than urine cytology. Therefore, its routine use is
not helpful for the diagnosis of BKVN (32).
However, in biopsy-proven BKVN, serial quantitative
PCR analysis of urine may be used to follow patients and to
assess the response to therapy (29).
Recently, themeasurement ofmessenger RNA for BKV
capsid protein VP1 in urine was proposed as a noninvasive
strategy to diagnose BKVN. The specificity and the sensitivity
of this method were shown to be as high as 93.8% and 93.9%,
respectively (33), but it is not in routine use.
PCR analysis of BKV DNA in the serum is a reliable
method of predicting BKV infection. The predictive value of
“a positive quantitative plasma PCR test” to predict BKVN is
50% and the negative predictive value is 100% (34). The pre-
dictive power of serum PCR tests can be further enhanced by
the quantification of viral DNA loads. Plasma viral load levels
of greater than 1104 copies/mL have a predictive value of
greater than 80%.
A patient with BKV loads exceeding 1104 copies/mL
in the plasma and 1107 copies in the urine has a high risk to
develop BKVN. The absence of viremia and viruria practi-
cally rules out a diagnosis of BKVN. BKViruria and
BKViremia most frequently occur during the first year af-
ter renal transplantation, as asymptomatic events never
leading to BKVN. Approximately 50% of the viremic epi-
sodes are transient, one-time phenomena. In some pa-
tients, persistent viremia can be seen as a prodromal stage
of BKVN. But PCR assays are not standardized and proto-
cols vary from laboratory to laboratory. The interlabora-
tory variability of the results can exceed 1 log 10.
Histology
Tissue biopsy is considered the gold standard for doc-
umentation of BKVN (35), ideally containing two cores of
cortex andmedulla obtainedwith a 15-G needle (36). Indeed,
BKVN often only focally affects renal tubules and collecting
ducts and becomes eventually confluent, affecting most pa-
renchyma (Fig. 2). Thus, the diagnosis of BKVN may be
missed in 25% to 37% of biopsy samples consisting of only
one small core cortex.
BKVN can present with different histologic patterns
and progress through various stages. Intranuclear viral inclu-
sion bodies in epithelial cells and virally induced tubular ep-
ithelial cell injury and lysis define BKVN in renal allograft
(Fig. 3). Tubules infected by BKV show numerous cytopathic
changes, including anisonucleosis of the nuclei with hyper-
chromasia and smudging or clumping or peripheral mar-
gination of chromatin. Infected cells have nuclei that are
enlarged by 2 to 5 times, with associated N/C ratio. The
most characteristic sign is the presence of basophilic in-
tranuclear inclusions with no prominent surrounding halo
and occasional ground glass appearance (31).
Three stages have been defined recently.
Stage A
Signs of viral activation are found in cortical or medul-
lary tubular cross-sections. Viral activation is only identified
by positive intranuclear immunohistochemical or in situ hy-
bridization signals. Interstitial inflammation is absent or
minimal. Tubular atrophy and interstitial fibrosis do not in-
volve more than 10% of the biopsy sample.
FIGURE 1. Decoy cells in urine cytology preparation
showing a cluster of intranuclear viral inclusion bearing de-
coy cells (arrows). Papanicolaou-stained thinprep smear.
FIGURE 2. Representative histological field of BKVpoly-
oma virus-associated nephropathy.
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Stage A is diagnosed early and responds to therapy with
favorable long-term graft function and survival.
Stage B
Signs of viral activation are found in cortical and med-
ullary tubular cross-sections with conspicuous virally in-
duced epithelial cell lysis, denudation of tubular basement
membrane and interstitial edema. Mononuclear inflamma-
tory cell infiltrates are common. Interstitial fibrosis and tu-
bular atrophy are minimal to moderate, remaining less than
50%. Stage B is subdivided into three groups according to
virally induced tubular injury or inflammation (stage B1,
25% involvement of the biopsy cores; stage B2, 26%–49%
involvement of the biopsy cores; and stage B3,50% involve-
ment of biopsy cores).
Regression from stage B to stage A may be observed
during the resolution of BKVN.
Stage C
Signs of viral replication are associated with tubular
epithelial injury. Interstitial inflammation can vary from
minimal to more important. Fibrosis and tubular atrophy
injury resulting from the viral injury involve more than 50%
of the tissue sample.
Fibrosis andtubularatrophy found instageCare irrevers-
ible and associated with severe allograft dysfunction or loss.
Establishing the diagnosis of BKVN definitively can be
challenging because not only does the histologic picture of
BKVNmimic acute cellular rejection, but also both processes
may be present concurrently. To distinguish acute rejection
from BKVN easily, the use of tubular expression of MHC-
class II (HLADR) or C4d along peritubular capillaries is nec-
essary. Hirsch (37) stated that immunohistochemistry using
antibodies against the large T antigen of SV40 increased the
sensitivity and specificity of the diagnosis. However, this test
is unable to distinguish BKV from JCV or SV40 (Fig. 4). Only
a minority of cases seems to coactivate BKV and JCV simul-
taneously. In addition to immunohistochemistry, in situ hy-
bridization and electron microscopy can be used to confirm
the diagnosis of BKVN.Ultrastructurally, polyomaviruses are
found in nuclei as crystalloid particles of approximately 40
nm in diameter, distinguishing polyomaviruses from other
viruses such as adenovirus or cytomegalovirus based on size.
In practice, several clinical approaches are used for
early diagnosis of BKVNusing urine cytology, BKviral load in
urine and in blood, and finally renal allograft biopsy. Ramos
et al. (38) used a screening protocol based on urine cytology.
This same strategy is proposed byHirsch et al. (27). However,
Brennan et al. (23) and Ginevri et al. (26) proposed to follow
BKViruria and BKViremia. The last strategy, proposed by
Buehrig et al. (18), uses routine surveillance biopsies to iden-
tify patients with subclinical BKVN.
Treatment
Reduction of immunosuppression has long been a
cornerstone in controlling BKV infection, but this strategy
is not always curative and can put the allograft at risk of
acute rejection.
In practice, the primary mode of intervention is to de-
crease or stopMMF. At the same time, the calcineurin inhib-
itor blood level is reduced to achieve a cyclosporine trough
level between 100 and 150 ng/mL or a tacrolimus trough level
lower than 6 ng/mL (18, 30, 38). The switch “tacrolimus to
cyclosporine” or “tacrolimus to sirolimus” is also reported
(30). But a rapid reduction in immunosuppressionmay result
in an insufficient control of immunity, leading to acute rejec-
tion. Randhawa et al. (3) reported improved outcomes with
graft loss and higher rates of viral clearance after a judicious
decrease in the immunosuppressive therapy. However, in pa-
tients with progressive graft dysfunction not responding to
this reduction, antiviral treatment should be considered. An-
tiviral drugs such as acyclovir, ganciclovir, foscarnet, and
ribavirin have been shown to have no effect on the BKVN
evolution. Initial case reports suggested that cytaribine, vidar-
ibine (39), and amantadine (40) may be effective treatments
FIGURE 3. BK-virus nephropathy. The nephropathy is
characterized by typical intranuclear viral inclusion bodies
in tubular epithelial cells (arrowheads). Tubules show se-
vere virally induced epithelial cell necrosis and denuda-
tion of basement membranes (arrows). Periodic acid
Schiff’s reagent-stained paraffin section. FIGURE 4. Immunohistochemical incubation on paraffin-
embedded tissue to detect the simian virus 40-T antigen A
positive staining reaction is seen in infected epithelial cell
nuclei lining one tubule. Note the focal nature of BK-virus
nephropathy.
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against BKV, but subsequent experiences have not shown any
benefit. Other antiviral agents such as cidofovir, leflunomide,
FK778, quinolone antibiotics, and intravenous immunoglob-
ulin (4, 40) are used with anecdotal success. Protocols and
success rates are heterogeneous, with graft loss ranging from
less than 10% to more than 80%. The efficacy of these treat-
ments is unclear, because reduction of immunosuppression
has been used along with all of these strategies. However, two
recent reports emphasize encouraging results, the first with
very low-dose cidofovir antiviral therapy (0.25–1 mg/kg per
dose without probenecid) and the second with leflunomide.
Cidofovir is a nucleoside analogue licensed for treat-
ment of cytomegalovirus retinitis in HIV-infected patients.
Its in vitro activity spectrum encompasses papovaviruses (in-
cluding the polyomavirus), adenoviruses, herpes viruses, iri-
diviruses, and poxviruses. The use of cidofovir is limited by its
nephrotoxicity, particularly at the doses used for the treat-
ment of systemic cytomegalovirus infection (5 mg/kg weekly),
and therefore is contraindicated in patients with impaired renal
function. In addition, proteinuria and elevation in serum creat-
inine were seen in 39% and 24% of patients treated with high-
dose cidofovir.
However, pharmacokinetic studies have demonstrated
that cidofovir is highly concentrated in urine and renal tissue,
the primary sites of BKV infection. Indeed, approximately
75% to 80% of the cidofovir dose is excreted in the urine
unchanged within 24 hr after administration. Kuypers et al.
(41) have shown that adjuvant low-dose cidofovir therapy in
addition to reduction of immunosuppression treatment has a
beneficial effect in renal transplant recipients with biopsy-
proven BKVN. Low-dose cidofovir therapy was devoid of se-
rious adverse effects. Eight of 21 patients with BKVN were
treated with weekly adjuvant low-dose cidofovir (0.5–1.0
mg/kg body weight) in addition to reduction of immunosup-
pression for a minimum of 4 and a maximum of 10 weeks.
Graft function had deteriorated at the time of BKVN diagno-
sis but seemed to stabilize after cidofovir treatment. Blood
viral load decreased in all patients after treatment and became
negative in only six patients (75%). Viral load in the urine
tended to decrease but remained detectable in all patients
after therapy. However, 9 of 13 recipients who received no
adjuvant cidofovir therapy lost their graft within the year after
diagnosis of BKVN. Blood viral load decreased initially and
became negative in only six patients (46%). This report and
others (42–44) confirm that adjuvant cidofovir treatment re-
sults in an improved clinical course and in a blood viral load
reduction in most patients. These preliminary results are en-
couraging butmust be confirmedby a randomized controlled
study to prospectively evaluate the effect of cidofovir on graft
function, graft survival, and viral load compared with a re-
duction of immunosuppression.
Leflunomide is an immune suppressant drug, used for
the treatment of rheumatoid arthritis. More recently, it has
been advocated as an immunosuppressive agent after kidney
transplantation to allow reduction in the dose of nephrotoxic
drugs, to retard the development of chronic rejection and to
protect against viral infections, including cytomegalovirus,
herpesvirus, and BKV. Leflunomide is rapidly metabolized to
A77 1726, its active metabolite. Its mechanism of action
seems to involve the inhibition of a mitochondrial enzyme
necessary for orotate synthesis in the de novo pathway to
uridine, and the inhibition of certain tyrosine kinases in-
volved in T-cell and B-cell signaling cascades. Josephson et al.
(45) studied 26 patients with biopsy-proven BKVN. In all
patients, MMF was stopped at the time leflunomide was
started. The daily maintenance dose of leflunomide was 40
mg after a loading dose of 100 mg per day during 5 days.
Tacrolimus trough levels were maintained at 4 to 6 ng/mL.
Leflunomide treatment of patients with BKVN reduces BKV
load in blood and in urine and prevents reoccurrence of the
nephropathy. Only 4 of 26 BKVN recipients lost their renal
graft (15%) during this study. Leflunomide blood levels
above 40 g/mL were necessary for antiviral action. No seri-
ous adverse event was reported in this article. As is the case for
cidofovir, a randomized controlled study comparing lefluno-
mide and immunosuppressive reduction must confirm this
preliminary study.
Fluoroquinolone antibiotics seem to inhibit BK viral
replication in vitro. Recently, five clinically relevant fluoro-
quinolones (gatifloxacin, ofloxacin, ciprofloxacin, trovo-
floxacin, and levofloxacin) were tested and demonstrated
their ability to inhibit viral replication SV40 in permissive
monkey’s cells (46,47).A recent study showed thepositive effect
of a short course of gatifloxacin (500 mg orally once daily) on
renal transplant recipients excreting BKV in urine (48). More-
over, exposure to ciprofloxacine seems to decrease theBKV load
in another study reported in bonemarrow transplant recipients
(49). Again prospective randomized studies are necessary to
evaluate this antiviral action.
Outcome of Infection
Specific antiviral strategies to treat patients with BKVN
are thus poorly defined. In most cases, BKVN was treated by
reduction of immunosuppressive therapy and sometimes ad-
ditionally antiviral drugs (currently cidofovir or lefluno-
mide). Graft loss as a result of BKV reactivation varies in
many reports from 45% (4) to 67% (3). The timing for the
initial diagnosis of BKVN is critical for therapeutic success and
good outcome. A level of renal dysfunction defined as serum
creatinine more than 2.2 mg/dL at the time of diagnosis of
BKVNwas correlated with poorer long-term graft survival (30).
BKVN seems to be an indicator of intense or overim-
munosuppression. Prevention of BKVN may be a better
strategy than treatment of BKV infection. A therapeutic
intervention may already be initiated when patients
present significant signs of BK viral reactivation but lack
histologic proof of BKVN. BKViremia is commonly absent
and may serve as the earliest indicator of overimmunosuppres-
sion. Brennan et al. (23) have prevented the progression of
BKVN in a large cohort of patients with prospectivemonitoring
of urine and blood BK viral load, and preemptive withdrawal of
theantimetabolite agentondevelopmentofBKViremiaandBK-
Viruria. Another study showed a resolution or a decrease of BK-
Viruria or viremia only with reduction of immunosuppressive
standard drugs (50).
Retransplantation
Retransplantation after BKVN has been reported in
some cases with recurrence of the disease in only approxi-
mately 12% of all patients (50). This favorable outcome after
retransplantation may be caused by the presence of HLA C7
in the second transplant (35, 50, 51). The allograft nephrec-
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tomy did not protect against the recurrence of BKVN (52).
Intense immunosuppression and retransplantation during
BKV replication should be avoided. BKV blood viral load
must be as low as possible.
Preemptive retransplantation is possible if immuno-
suppressive treatment is reduced in patients at both 40 and 12
weeks before retransplantation. This period is necessary to
decrease the BKV plasma loads. Since latent BKV remain a
source of reinfection in autologous kidney and bladder tissue,
the notion that nephrectomy is unnecessary disregards the
HLA-dependent differences in antiviral immune control, as
the latter is likely to be more effective in autologous as com-
pared to allogenic tissue. But, after graft nephrectomy,
changes in BKV loads are more easily attributed at the new
transplant (52).
CONCLUSIONS
BKVN has become an important problem in renal
transplantation because of more powerful immunosuppres-
sive strategies. Its development confers a poor prognosis for
renal graft survival and an early diagnosis is necessary to
achieve favorable outcome. The presence of BKVN suspected
by BK viral load in urine and blood must be proved by renal
biopsy. However, efficient treatment is still a great challenge
to nephrologists. A quick reduction in the immunosuppres-
sive treatment is the first step. Other treatments still need
validation.
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